MYOS (NASDAQ:MYOS) released its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Bloomberg Earnings reports. The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.14 million. MYOS had a negative net margin of 603.47% and a negative return on equity of 93.20%.
MYOS stock traded up $0.06 during mid-day trading on Friday, reaching $1.69. The company’s stock had a trading volume of 370 shares, compared to its average volume of 15,730. The stock has a market cap of $15.68 million, a P/E ratio of -3.76 and a beta of 0.78. MYOS has a 12 month low of $1.04 and a 12 month high of $2.02. The firm’s 50 day simple moving average is $1.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.53 and a quick ratio of 2.06.
Separately, ValuEngine downgraded shares of MYOS from a “buy” rating to a “hold” rating in a research report on Tuesday.
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.